LIFEVANTAGE CORP Intangible Assets, Net (Excluding Goodwill)
LIFEVANTAGE CORP (LFVN) had Intangible Assets, Net (Excluding Goodwill) of $3.06 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-27
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $3.06M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $3.19M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $3.32M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $245.00K.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $3.06M 10-K · filed 2026-08-27 |
| 2026-03-31 | $3.19M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $3.32M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $245.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $245.00K 10-K · filed 2026-08-27 |
| 2025-03-31 | $224.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $257.00K 10-Q · filed 2025-02-05 |
| 2024-09-30 | $290.00K 10-Q · filed 2024-10-29 |
| 2024-06-30 | $323.00K 10-K · filed 2025-09-04 |
| 2024-03-31 | $356.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $389.00K 10-Q · filed 2024-01-30 |
| 2023-09-30 | $422.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $455.00K 10-K · filed 2024-08-28 |
| 2023-03-31 | $488.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $521.00K 10-Q · filed 2023-02-02 |
| 2022-09-30 | $554.00K 10-Q · filed 2022-11-02 |
| 2022-06-30 | $587.00K 10-K · filed 2023-08-28 |
| 2022-03-31 | $620.00K 10-Q · filed 2022-05-03 |
| 2021-12-31 | $653.00K 10-Q · filed 2022-02-01 |
| 2021-09-30 | $686.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $719.00K 10-K · filed 2022-08-23 |
| 2021-03-31 | $752.00K 10-Q · filed 2021-04-29 |
| 2020-12-31 | $785.00K 10-Q · filed 2021-02-02 |
| 2020-09-30 | $818.00K 10-Q · filed 2020-11-03 |
| 2020-06-30 | $851.00K 10-K · filed 2021-08-19 |
| 2020-03-31 | $884.00K 10-Q · filed 2020-05-05 |
| 2019-12-31 | $917.00K 10-Q · filed 2020-01-28 |
| 2019-09-30 | $950.00K 10-Q · filed 2019-10-30 |
| 2019-06-30 | $983.00K 10-K · filed 2020-08-18 |
| 2019-03-31 | $1.02M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $1.05M 10-Q · filed 2019-02-04 |
| 2018-09-30 | $1.08M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $1.11M 10-K · filed 2019-08-14 |
| 2018-03-31 | $1.15M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $1.18M 10-Q · filed 2018-02-07 |
| 2017-09-30 | $1.21M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $1.25M 10-K · filed 2018-08-15 |
| 2017-03-31 | $1.67M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $1.70M 10-Q · filed 2017-02-08 |
| 2016-09-30 | $1.73M 10-Q · filed 2016-12-12 |
| 2016-06-30 | $1.74M 10-K · filed 2017-09-07 |
| 2016-03-31 | $1.78M 10-Q/A · filed 2016-07-19 |
| 2015-12-31 | $1.81M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $1.84M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $1.88M 10-K · filed 2016-12-12 |
| 2015-03-31 | $1.91M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $1.95M 10-Q · filed 2015-02-04 |
| 2014-09-30 | $1.98M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $2.01M 10-K · filed 2015-09-01 |
| 2013-06-30 | $1.75M 10-K · filed 2014-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |